CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs.… BusinessWire Jun 17, 2024 A BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
